The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

Puig, Noemí; Sarasquete, María E; Alcoceba, Miguel; Balanzategui, Ana; Chillón, María C; Sebastián, Elena; Marín, Luis A; Díaz, Marcos González; San Miguel, Jesús F; Sanz, Ramón García

Puig, Noemí; Sarasquete, María E; Alcoceba, Miguel; Balanzategui, Ana; Chillón, María C; Sebastián, Elena; Marín, Luis A; Díaz, Marcos González; San Miguel, Jesús F; Sanz, Ramón García.

Affiliation

Puig N; Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain.

Ann Hematol ; 92(1): 97-100, 2013 Jan.

Article in En | MEDLINE | ID: mdl-22956183

Subject(s)

Bone Marrow Examination/methods; Bone Marrow/pathology; Cell Separation/methods; Gene Rearrangement, B-Lymphocyte; Multiple Myeloma/pathology; Real-Time Polymerase Chain Reaction/methods; Syndecan-1/analysis; Clone Cells/pathology; DNA, Neoplasm/genetics; Humans; Myeloma Proteins/genetics; Neoplasm, Residual/diagnosis; V(D)J Recombination

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Bone Marrow Examination / Gene Rearrangement, B-Lymphocyte / Cell Separation / Syndecan-1 / Real-Time Polymerase Chain Reaction / Multiple Myeloma Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2013 Type: Article Affiliation country: Spain

Fulltext

XML

PubMed Links

Search on Google